Tissue Engineering

Group leader: Ander Izeta, Ph.D.

Biodonostia HRI ander.izeta@biodonostia.org

Strategic Objectives

The central objective is to elucidate the ontogeny, expansion and differentiation capacity of precursor cells in human and mouse dermis, with the ultimate purpose of facilitating their therapeutic use through the generation of tissue engineering constructs and/or helping to clarify their possible contribution to carcinogenic processes or other types of pathologies.

Main lines of research

  • Basic research into the ontogeny of isolated mesodermal and neurogenic lineages of human and mouse dermis (lineage records) and their drift towards neural and musculoskeletal lineages.
  • Pre-clinical research to advance towards the clinical use of precursor skin cells. Their utility in different animal models is being explored (muscle damage, chronic rotator cuff damage, distraction osteogenesis or Alzheimer’s) through a range of collaborations.
  • Clinical trials to analyse the efficacy and safety of autologous hair follicle transplants to cure chronic ulcers.
  • Study of the implication of precursor cells in the etiopathogenesis of dermal neurofibromas or other derived tumours of the peripheral nervous system and/or the neural crest.
  • Studies related to precursor cells and industrial applications in the field of cosmetics.

Team Members

Name Surname Center E-mail
Sandra Fuertes Alvarez Biodonostia HRI sandra.fuertes@biodonostia.org
Carmen Garde Orbaiz Donostialdea IHO mariacarmen.gardeorbaiz@osakidetza.eus
Leire Gardeazabal Martinez De Espronceda Biodonostia HRI leire.gardeazabal@biodonostia.org
Maria Begoña Jimeno Badiola Donostialdea IHO mbegona.jimenobadiola@osakidetza.eus
Hector Lafuente Echevarria Biodonostia HRI hector.lafuente@biodonostia.org
Nerea Ormaechea Pérez Donostialdea IHO
Virginia Pérez López Biodonostia HRI virginia.perez@biodonostia.org
Juan Pablo Sanz Jaca Donostialdea IHO juanpablo.sanzjaka@osakidetza.eus
Susana Vildosola Esturo Donostialdea IHO susana.vildosolaesturo@osakidetza.eus
Laura Yndriago Acha Biodonostia HRI laura.yndriago@biodonostia.org

Scientific Output

Originals

Published: 10 / 51

Stress urinary incontinence animal models as a tool to study cell-based regenerative therapies targeting the urethral sphincter.

Herrera-Imbroda B, Lara MF, Izeta A, Sievert KD, Hart Melanie L.

Adv. Drug Deliv. Rev.2015; 82-83: 106-116. FI: 15.038 (Q1).

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.

Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R, ADVANZ and ADVANZ-3 Investigators.

Aids. 2015; 29: 1493-1504. FI: 5.554 (Q1).

Facial lesions in frontal fibrosing alopecia (FFA): Clinicopathological features in a series of 12 cases.

Lopez-Pestana A, Tuneu A, Lobo C, Ormaechea N, Zubizarreta J, Vildosola S, Del Alcazar E.

J. Am. Acad. Dermatol. 2015; 73. FI: 4.449 (Q1).

Cell Therapy for Stress Urinary Incontinence. Tissue Engineering Part B-Reviews.

Hart ML, Izeta A, Herrera-Imbroda B, Amend B, Brinchmann JE.

2015; 21: 365-376. FI: 3.892 (Q2).

Reflections on how wound healing-promoting effects of the hair follicle can be translated into clinical practice.

Jimenez F, Poblet E, Izeta A.

Exp. Dermatol. 2015; 24: 91-94. FI: 3.762 (Q1).

Amniotic Membrane Modifies the Genetic Program Induced by TGF beta, Stimulating Keratinocyte Proliferation and Migration in Chronic Wounds. PLoS One.

Alcaraz A, Mrowiec A, Insausti CL, Bernabe-Garcia A, Garcia-Vizcaino EM, Lopez-Martinez MC, Monfort A, Izeta A, Moraleda JM, Castellanos G, Nicolas FJ.

2015; 10. FI: 3.234 (Q1).

A nodule on the scalp of an elderly patient.

del Alcazar Viladomiu E, Tuneu A, Arregui MA, Feito J.

Int. J. Dermatol. 2015; 54: 637-639. FI: 1.312 (Q3).

HOME AND AMBULATORY ARTIFICIAL NUTRITION (NADYA) GROUP REPORT, HOME PARENTERAL NUTRITION IN SPAIN, 2014.

Wanden-Berghe C, Pereira JL, Compes CC, Moreno JM, Perez A, Burgos R, Gomez C, Virgili N, Penacho MA, Martinez C, Garde C, Gonzalo M, Sanz A, Alvarez J, Sanchez EA, Martin T, Campos C, Matia P, Zugasti A, Carabana F, Garcia MV, Ponce MA, Suarez JP, Martinez C, de Luis D, Apezetxea A, Luengo LM, Diaz P, Gil MC, del Olmo MD, Garcia PL, Vidal A, Joaquin C, Sanchez-Vilar O, Laborda L, NADYA-SENPE.

Nutr. Hosp. 2015; 32: 2380-2384. FI: 1.040 (Q4).

A home enteral nutrition (HEN); Spanish registry of NADYA-SENPE group; for the year 2013.

Wanden-Berghe C, Alvarez J, Burgos R, Cuerda C, Matia P, Luengo LM, Gomez C, Perez A, Calleja A, Martinez MA, Laborda L, Campos C, Leyes P, Irles JA, Suarez JP, Cardona D, Gonzalo M, Penacho MA, Ballesta C, Rabassa A, Garde C, Canovas B, Moreno JM, del Olmo MD, Carabana F, Arraiza C, Mauri S, Sanchez-Vilar O, Virgili N, Miserachs N, Apezetxea A, Pereira MA, Ponce MA, Grp NADYA-SENPE.

Nutr. Hosp. 2015; 31: 2518-2522. FI: 1.040 (Q4).

Cutaneous neonatal lupus erythematosus.

Jaka A, Zubizarreta J, Ormaechea N, Tuneu A.

Indian J. Dermatol. Venereol. Leprol. 2012; 78: 775-131. FI: 0.979 (Q4).

Reviews

Published: 2 / 2

Biology of the eyelash hair follicle: an enigma in plain sight.

Paus R, Burgoa I, Platt CI, Griffiths T, Poblet E, Izeta A.

British Journal Of Dermatology. 2016; 174: 741-752. FI: 4,706 (Q1).

Cell-based product classification procedure: What can be done differently to improve decisions on borderline products?

Izeta A, Herrera C, Mata R, Astori G, Giordano R, Hernández C, Leyva L, Arias S, Oyonarte S, Carmona G, Cuende N.

Cytotherapy. 2016; 18: 809-815. FI: 3,203 (Q2).

Editorials

Published: 8 / 8

A reddish nodule on the nose.

del Alcazar E, Gutierrez MP, Lobo C, Tuneu A.

Int. J. Dermatol. 2015; 54: 19-20. FI: 1.312 (Q3).

Fever and skin lesions in an immunocompromised patient.

del Alcazar E, Jaka A, Camino N, Gancho G, Tuneu A.

Clin. Exp. Dermatol. 2015; 40: 219-221. FI: 1.092 (Q3).

Purulent Discharge from the Nipples: A Quiz Zuska’s disease.

Tuneu A, Arregui MA, Jaka A, Ormaechea N.

Acta Derm.-Venereol. 2014; 94: 492-0. FI: 4.244 (Q1).

The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders’ concerns.

Cuende N, Boniface C, Bravery C, Forte M, Giordano R, Hildebrandt M, Izeta A, Dominici M, Int Soc Cellular Therapy.

Cytotherapy. 2014; 16: 1597-1600. FI: 3.100 (Q2).

Nodular skin lesions in a patient from Nicaragua.

Perez-Fernandez N, Jaka-Moreno A, de la Caba I, Goenaga-Sanchez MA.

Enferm. Infecc. Microbiol. Clin. 2013; 31: 114-115. FI: 1.478 (Q4).

Reddish Nodule on the Hand: A Quiz.

Panes-Rodriguez A, Vildosola-Esturo S, Rodriguez-Perez I, Tuneu-Valls, A, Del Alcazar-Viladomiu E.

Acta Dermato-Venereologica. 2016; 96: -. FI: 3,653 (Q1).

Editorial: Role of Stem Cells in Skeletal Muscle Development, Regeneration, Repair, Aging, and Disease.

Muñoz-Cánoves P, Carvajal JJ, Lopez de Munain A, Izeta A.

Frontiers In Aging Neuroscience. 2016; 8: 95-95. FI: 4,504 (Q1).

Alopecic Lesions on the Scalp in a Young Woman: A Quiz.

del Alcazar E, Lopez A, Ibarbia S, Gutierrez MP, Tuneu A.

Acta Dermato-Venereologica. 2016; 96: 285-287. FI: 3,653 (Q1).

Letters

Published: 10 / 10

Does fat get you skinny?.

Gutierrez-Rivera A, Izeta A.

Exp. Dermatol. 2015; 24: 740-741. FI: 3.762 (Q1).

Photodistributed neutrophilic dermatosis in a woman with Legionella pneumonitis.

Jaka A, Tuneu A, Ormaechea N, Zubizarreta J.

Int. J. Dermatol. 2014; 53: 209-210. FI: 1.227 (Q3).

Pseudoporphyria induced by imatinib mesylate.

Ormaechea N, Vildosola S, Jaka A, Tuneu A.

Int. J. Dermatol. 2014; 53: 143-144. FI: 1.227 (Q3).

Violaceous nodules on the leg of a patient with multiple myeloma.

Ormaechea-Perez N, Vildosola-Esturo S, Aseginolatza-Zabaleta B, Lobo-Moran C, Jaka-Moreno A, Del alcazar-Viladomiu E, Tuneu-Valls A.

Int. J. Dermatol. 2014; 53: 296-298. FI: 1.227 (Q3).

Alopecia areata in a patient receiving infliximab.

Ormaechea-Perez N, Lopez-Pestana A, Munagorri-Santos AI, Jaka A, Tuneu-Valls A.

Indian J. Dermatol. Venereol. Leprol. 2013; 79: 529-213. FI: 1.206 (Q3).

Lack of concordance in parapneumonic effusion management in Central European children: Spain is not different.

Moral L, Sánchez-Solis M, Cambra FJ, Navarro M, Eizaguirre I.

Pediatric Pulmonology. 2016; 51: 1111-1112. FI: 2,758 (Q1).

Does Schwann cell dedifferentiation originate dermal neurofibromas?

Iribar H, Jaka A, Ormaechea N, Tuneu A, Izeta A, Gutiérrez-Rivera A.

Experimental Dermatology. 2016; 25: 901-903. FI: 2,679 (Q1).

Superficial granulomatous pyoderma. Report of 2 cases treated with topical tacrolimus.

Ormaechea-Pérez N, López-Pestaña A, Lobo-Morán C, Tuneu-Valls A.

Actas Dermosifiliogr. 2013; 104: 721-724. FI: 0.000 (Q0).

Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.

Borja-Consigliere HA, López-Pestaña A, Vidal-Manceñido MJ, Tuneu-Valls A.

Actas Dermosifiliogr. 2014; 105: 716-718. FI: 0.000 (Q0).

Dyshidrosiform linear immunoglobulin a dermatosis.

Borja-Consigliere HA, Ormaechea-Pérez N, Lobo-Morán C, Tuneu-Valls A.

Actas Dermosifiliogr. 2014; 105: 429-430. FI: 0.000 (Q0).

Others

Published: 1 / 1

Sondas biodegradables para la prevención de las fístulas de hipospadias. Estudio preliminar experimental.

Ramos JL, Aldazabal P, Zuza E, Sarasúa JR, Arrieta A, Villanueva A, Eizaguirre I.

Cir. Pediatr. 2013; 26: 91-94. FI: 0.000 (Q0).

Projects

Projects 5 / 5

Caracterización funcional de las células troncales adultas SOX2 positivas en la Dermis humana y murina.

Investigador principal: Ander Izeta Permisán. Entidad financiadora: ISCIII Instituto de Salud Carlos III. Año inicio: 2014. Año final: 2016.

Implicación de los microRNAs en la actualidad y resistencia a Sunitinib en carcinoma renal de células claras y asociados al envejecimiento.

Investigador principal: Juan Pablo Sanz Jaca. Entidad financiadora: Gobierno Vasco, Departamento de Salud. Año inicio: 2014. Año final: 2017.

Regenerative Sphincter Therapy (REST).

Investigador principal: Ander Izeta Permisán. Entidad financiadora: European Cooperation in Science and Technology Cost. Año inicio: 2013. Año final: 2017.

Strategies to promote vascularization in skeletal muscle tissue engineered constructs.

Investigador principal: Ander Izeta Permisán. Entidad financiadora: POCTEFA-Interreg IV A. Año inicio: 2013. Año final: 2015.

Hueso inyectable para el tratamiento de fracturas, combinando hidrogeles de última generación y productos alogénicos.

Investigador principal: Ander Izeta Permisán. Entidad financiadora: Gobierno de España, Ministerio de Economía y Competitividad. Año inicio: 2012. Año final: 2015.